Search company, investor...

Amicogen

amicogen.com

Founded Year

2000

Stage

IPO | IPO

Total Raised

$230K

Date of IPO

9/12/2013

Market Cap

385.38B

About Amicogen

Amicogen (KOSDAQ: 092040) is a global industrial biotechnology company focusing on Specialty Enzymes (CX, SP, etc.) and Bio-ingredient (N-Acetylglucosamine, Pinitol/D-Chiro-inositol, Collagen Peptide/ Collagen Tri Peptide, Fucoxanthin, etc.). Amicogen was founded in 2000 and is based in Gyeongsangnam-do, South Korea.

Headquarters Location

64, Dongbu-ro 1259beon-gil Jinseong-myeon, Jinju-si

Gyeongsangnam-do, 52621,

South Korea

+82 055 - 759 - 6161

Missing: Amicogen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Amicogen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Amicogen Patents

Amicogen has filed 6 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Transcription factors
  • Acneiform eruptions
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/25/2018

10/18/2022

Transcription factors, Molecular biology, Nicotinic antagonists, Peptides, Amines

Grant

Application Date

6/25/2018

Grant Date

10/18/2022

Title

Related Topics

Transcription factors, Molecular biology, Nicotinic antagonists, Peptides, Amines

Status

Grant

Latest Amicogen News

Lysando AG and Amicogen Inc. Sign General Development Agreement

Oct 18, 2022

Download Lysando is constantly working on the development of new Artilysin®s. October 18, 2022 04:13 AM Eastern Daylight Time TRIESENBERG, Liechtenstein--( BUSINESS WIRE )--Lysando AG – market leader in the field of antimicrobial proteins – has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea. In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement. "Amicogen is our first choice for process development and scale-up of any new Artilysin®", says Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG. "This important step in our partnership with Amicogen will help our customers to significantly shorten the time-to-market of Artilysin®-powered products." Amicogen is an established and professional partner enabling Lysando to develop its own projects to market-readiness at maximum speed, thus further accelerating Lysando’s entry into the pharmaceutical industry. Ongoing projects targeting indications such as urinary tract infections or neurodermatitis are progressing well. About Amicogen Inc. Amicogen Inc (092040.KQ) is a CDMO and biotechnology company based in Jinju, South Korea. Amicogen is a leader in the development and production of specialty enzymes and proteins for the biopharmaceutical, food, cosmetics and other industries. One of Amicogen's core competencies is the use of new technologies such as directed gene evolution. The heart of the business is a novel approach that uses biocatalysts to replace chemical with enzymatic processes. These biocatalysts provide an environmentally friendly manufacturing process for downstream industries reducing emissions, simplifying production processes and increasing productivity. About Lysando AG Lysando AG is the market leader for antimicrobial proteins, so-called Artilysin®s. They can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin®s constitute an innovative, proprietary and environmentally friendly technology with a wide range of applications: in human and veterinary medicine, but for example also in cosmetics. Lysando AG's research facility is Lysando Innovations Lab GmbH located in Regensburg's BioPark. BioPark Regensburg fosters companies in biotechnology, medical technology, diagnostics & analytics as well as the local healthcare management. Contacts

Amicogen Frequently Asked Questions (FAQ)

  • When was Amicogen founded?

    Amicogen was founded in 2000.

  • Where is Amicogen's headquarters?

    Amicogen's headquarters is located at 64, Dongbu-ro 1259beon-gil, Gyeongsangnam-do.

  • What is Amicogen's latest funding round?

    Amicogen's latest funding round is IPO.

  • How much did Amicogen raise?

    Amicogen raised a total of $230K.

  • Who are the investors of Amicogen?

    Investors of Amicogen include Mirae Asset Venture Investment, Hyundai Venture Investment Corporation and KIWOOM Investment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.